- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05622201
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults (RCT-RITS)
Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce. An inflammatory modulating drug rituximab, cluster of differentiation antigen 20 antibodies (anti-CD20 antibodies), is a standard treatment for e.g. multiple sclerosis.
The investigators aim to test rituximab in a randomised placebo-controlled double-blinded, add-on treatment trial in 120 participants (18-55 years) with schizophrenia spectrum disorder. Sampling from blood for analyses of inflammatory mediators are investigated at gene and protein levels and resting state functional magnetic resonance imaging (rsfMRI) and lumbar puncture are optional. Biomarkers will be investigated in relation to treatment response.
Family member(s) to the patient and the patient (separate) will be asked to participate in a qualitative interview by an independent researcher after 3 months.
Study Overview
Status
Intervention / Treatment
Detailed Description
Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce. Rituximab (anti-CD20 antibodies), a standard treatment for multiple sclerosis in Sweden, is an inflammatory modulating drug. In a small open pilot trial, markedly ill, treatment-resistant participants with schizophrenia spectrum disorder were treated with a single- dose rituximab (1000 mg), as add-on treatment to antipsychotics in Örebro, Sweden (2019-2022). Large improvements in all types of psychotic symptoms were evident, with long-lasting effects and few side-effects in most of the participants.
This is a proof-of-concept study based on our earlier findings. The investigators will conduct a multicenter, placebo-controlled, double-blinded, add-on intervention study for 120 participants with schizophrenia spectrum disorder (18-55 years). Sampling from blood for analyses of inflammatory mediators are investigated at gene and protein levels and rsfMRI and lumbar puncture are optional at baseline and endpoints. Biomarkers will be investigated in relation to treatment response.
Participants are assessed at five time-points; week 0, 2, 7, 12 (endpoint I) and 24 (endpoint II).
Research questions:
I Does the addition of rituximab to standard psychiatric treatment improve psychotic symptoms in SSD?
II Does overall disability improve with the addition of rituximab?
III Are clinical or biological markers related to treatment response?
IV Is rituximab safe and well tolerated by participants with SSD?
In addition family member(s) to the patient will be asked to participate in a qualitative interview by a researcher after 3 months on changes in the patient's mood and anxiety level, general functioning, behaviours, energy level, psychotic symptoms, motivation, emotional reciprocity and insight to enable a qualitative analysis. We will also ask them about their general thoughts on the study. In addition we will interview the patient after 3 months using qualitative methods.
We also aim study changes in negative symptoms with the Motivation and pleasure- self report (MAP-SR) in addition to the Positive and Negative Syndrome Scale (PANSS) scale and Self-evaluation of Negative Symptoms (SNS). Childhood onset neuropsychiatric symptoms will be investigated retrospectively by the use of Five-to-Fifteen Brief (FTF-Brief).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Susanne Bejerot, MD,PhD
- Phone Number: 46 0701655102
- Email: susanne.bejerot@oru.se
Study Locations
-
-
-
Örebro, Sweden, 701 85
- Recruiting
- Orebro University Hospital
-
Contact:
- Susanne Bejerot, MD
- Phone Number: 0701655102
- Email: susanne.bejerot@oru.se
-
Contact:
- Axel Nordenskjöld, MD
- Phone Number: 070-6049589
- Email: axel.nordenskjold@oru.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ages 18 to 55 years
- duration of illness exceeding 1 year
- diagnosed with Schizophrenia spectrum disorder (SSD) according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- if female and with any risk for pregnancy, willing to use contraceptives or abstinence if normal and preferred lifestyle.
- participants should be judged by the investigator to be lucid and oriented to person, place, time, and situation when giving the informed consent.
- insufficiently recovered from previous antipsychotic treatments.
- a minimum score of 4 (moderately ill) in Clinical global impression - severity (CGI-S) at baseline.
Exclusion Criteria:
- pregnancy or breast-feeding
- weight below 40 kg
- clinically relevant ongoing infection at the discretion of the physician
- chronic infections
- positive test for hepatitis B, hepatitis C, HIV, or tuberculosis
- malignancy currently or within 2 years prior to inclusion
- current severe heart failure (NYHA grade IV) or any other severe heart disease (e.g. or history of cardiac arrhythmia or myocardial infarction)
- any change of antipsychotic medication within the previous 4 weeks
- unable to make an informed decision to consent to the trial
- ongoing clozapine treatment
- ongoing immunomodulatory treatment
- treatments with monoclonal antibodies within 1 year before the inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituximab
Rituximab 1000 mg, infusion
|
Infusion
Other Names:
|
Placebo Comparator: Placebo
Saline infusion
|
Infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in psychotic symptoms
Time Frame: Baseline up to 12 weeks
|
Change in scores in the measure for psychotic symptoms "the Positive and Negative Syndrome Scale (PANSS)"
|
Baseline up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in functioning
Time Frame: Baseline up to week 12 and 24
|
Measuring overall disability with Personal and Social Performance Scale (PSP)
|
Baseline up to week 12 and 24
|
Proportion of responders to treatment, rated as much or very much improved with CGI-I
Time Frame: Baseline up to week 12 and 24
|
Improvement according to clinical rated Clinical Global Impression-Improvement (CGI-I)
|
Baseline up to week 12 and 24
|
Improvement since baseline
Time Frame: Baseline up to week 12 and 24
|
Improvement according to clinical rated Clinical Global Impression-Improvement (CGI-I)
|
Baseline up to week 12 and 24
|
Change in severity since baseline
Time Frame: Baseline up to week 12 and 24
|
Improvement according to clinical rated Clinical Global Impression-Severity (CGI-S)
|
Baseline up to week 12 and 24
|
Improvement in psychotic symptoms since baseline
Time Frame: Baseline up to week 24
|
Change in scores in the measure for psychotic symptoms "the Positive and Negative Syndrome Scale (PANSS)".
|
Baseline up to week 24
|
Change in self-rated overall health
Time Frame: Baseline up to week 12 and 24
|
Differences in patient self-rated health (VAS-health)
|
Baseline up to week 12 and 24
|
Patient-rated improvement
Time Frame: Baseline up to week 12 and 24
|
Patient's Global Evaluation of improvement (PGE) corresponding to the CGI-I scores
|
Baseline up to week 12 and 24
|
Inflammatory markers in blood and/or cerebro spinal fluid (CSF)
Time Frame: Baseline up to week 12 and 24
|
Baseline levels of inflammatory markers in relation to treatment response (optional)
|
Baseline up to week 12 and 24
|
Safety and tolerability of rituximab
Time Frame: Baseline up to week 12 and 24
|
Open questions and a questionnaire (AAR-Revised)
|
Baseline up to week 12 and 24
|
fMRI
Time Frame: Baseline up to week 12 and 24
|
Change in brain morphology and/or activity in fMRI (optional)
|
Baseline up to week 12 and 24
|
Patient-rated change in psychiatric symptoms
Time Frame: Baseline up to week 12 and 24
|
Mental health symptom domains (Level 1 Cross-cutting symptom measure of global symptom severity) in relationship to response.
|
Baseline up to week 12 and 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression
Time Frame: Baseline up to week 12 and 24
|
The depression item A6 in PANSS will be investigated separately
|
Baseline up to week 12 and 24
|
Negative symptoms
Time Frame: Baseline week 12 and week 24
|
The Negative Syndrome Scale assessed by the clinician will be compared to self-rated negative symptoms measured with the Motivation and pleasure- self report (MAP-SR) in order to study how well they are correlated.
|
Baseline week 12 and week 24
|
Qualitative assessment
Time Frame: 12-18 weeks after infusion
|
An informant will be interviewed on whether they can see changes in patients and patient will be interviewed separately on symptoms after 12 weeks
|
12-18 weeks after infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Susanne Bejerot, MD, PhD, Region Örebro Län
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 278825
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Spectrum and Other Psychotic Disorders
-
VA Office of Research and DevelopmentCompletedSchizophrenia Spectrum & Other Psychotic DisordersUnited States
-
New York State Psychiatric InstituteTemple University; The Zucker Hillside Hospital; Feinstein Institutes for Medical...Not yet recruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Laval UniversityCompletedSchizophrenia and Schizophrenia Spectrum PsychosisCanada
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingSchizophrenia | Schizo Affective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Psychiatric Hospital of the University of BaselActive, not recruitingHarm Reduction | Schizophrenia and Other Psychotic DisordersSwitzerland
-
University of California, San DiegoNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective Disorder | Other Primary Psychotic DisordersUnited States
-
Stanford UniversityCompletedPsychotic Disorders | Schizophrenia Spectrum DisordersUnited States
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States